Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors

Haemophilia

Volumn 15, Issue 1, 2009, Pages 3-10

  Berntorp, Erik ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bypassing agents; Coagulation; Haemophilia; Haemostasis; Inhibitors; Pharmacodynamics

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING; CONTINUOUS INFUSION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; HEMOPHILIA; HEMOSTASIS; HUMAN; PATIENT CARE; PRIORITY JOURNAL; REVIEW;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTORS; CHILD; FACTOR VIIA; HEMOPHILIA A; HEMOSTASIS; HUMANS; ISOANTIBODIES; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 63049090494     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01931.x     Document Type: Review

References (50)

1. Astermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: The FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
2. Teitel J, Berntorp E, Collins P et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia 2007; 13: 256-63.
3. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: A guideline from the United Kingdom Haemophilia Centre Doctors'Organisation. Br J Haematol 2006; 133: 591-605.
4. Lloyd Jones M, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors: A systematic review. Haemophilia 2003; 9: 464-520.
5. Hilgartner MW, Knatterud GL. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983; 61: 36-40.
6. Hilgartner M, Aledort L, Andes A, Gill J. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion 1990; 30: 626-30.
7. Négrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997; 77: 1113-9.
8. Tjønnfjord GE. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: The updated Norwegian experience. Haemophilia 2004; 10(Suppl. 2): 41-5.
9. DiMichele D, Négrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006; 12: 352-62.
10. Levi M, Peters M, Büller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: A systematic review. Crit Care Med 2005; 33: 883-90.
11. Key NS, Aledort LM, Beardsley D et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
12. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773-8.
13. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4: 367-71.
14. Lusher JM, Roberts HR, Davignon G et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 1998; 4: 790-8.
15. Négrier C, Dargaud Y, Bordet JC. Basic aspects of bypassing agents. Haemophilia 2006; 12(Suppl. 6): 48-53.
16. FEIBA VH. Anti-Inhibitor Coagulant Complex [package insert]. Westlake Village: Baxter Healthcare Corporation, 2005.
17. Váradi K, Négrier C, Berntorp E et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost 2003; 1: 2374-80.
18. Turecek PL, Váradi K, Gritsch H, Schwarz HP. FEIBA: Mode of action. Haemophilia 2004; 10(Suppl. 2): 3-9.
19. Krishnaswamy S, Nesheim ME, Pryzdial EL, Mann KG. Assembly of prothrombinase complex. Methods Enzymol 1993; 222: 260-80.
20. Turecek PL, Váradi K, Gritsch H, Schwarz HP. Factor Xa and prothrombin: Mechanism of action of FEIBA. Vox Sang 1999; 77(Suppl. 1): 72-9.
21. Gallistl S, Cvirn G, Leschnik B, Muntean W. Respective roles of factors II, VII, IX, and X in the procoagulant activity of FEIBA. Blood Coagul Fibrinolysis 2002; 13: 653-5.
22. Aledort L, Lee CA. Coagulation deficiencies: A look to the future. Haemophilia 2006; 12: 531-40.
23. Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol 2006; 124: 747-57.
24. Hoffman M, Monroe DM, Roberts HR. Human monocytes support factor X activation by factor VIIa, independent of tissue factor: Implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia. Blood 1994; 83: 38-42.
25. Kenet G, Lubetsky A, Gitel S, Luboshitz J, Varon D, Martinowitz U. Treatment of bleeding episodes in patients with hemophilia and an inhibitor: Comparison of two treatment protocols with recombinant activated factor VII. Blood Coagul Fibrinolysis 2000; 11(Suppl. 1): S35-8.
26. Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: Analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-6.
27. Villar A, Aronis S, Morfini M et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 2004; 10: 352-9.
28. Teitel JM. Recombinant factor VIIa versus aPCCs in haemophiliacs with inhibitors: Treatment and cost considerations. Haemophilia 1999; 5(Suppl. 3): 43-9.
29. Hedner U, Brun NC. Recombinant factor VIIa (rFVIIa): Its potential role as a hemostatic agent. Neuroradiology 2007; 49: 789-93.
30. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22: 1381-9.
31. Sørensen B, Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost 2004; 2: 102-10.
32. Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev 2003; 17(Suppl. 1): S1-5.
33. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989; 134: 1087-97.
34. Butenas S, Orfeo T, Brummel-Ziedins KE, Mann KG. Tissue factor in thrombosis and hemorrhage. Surgery 2007; 142(Suppl.): S2-14.
35. Shetty S, Vora S, Kulkarni B et al. Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients. Br J Haematol 2007; 138: 541-4.
36. Astermark J, Ekman M, Berntorp E. Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors. Br J Haematol 2002; 119: 342-7.
37. Allen GA, Hoffman M, Roberts HR, Monroe DM. Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia. Br J Haematol 2006; 134: 314-9.
38. Mehta R, Parameswaran R, Shapiro AD. An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents. Haemophilia 2006; 12(Suppl. 6): 54-61.
39. Young G, Blain R, Nakagawa P, Nugent DJ. Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastography. Haemophilia 2006; 12: 598-604.
40. Berntorp E. Options for treating acute bleeds in addition to bypassing agents: Extracorporeal immunoadsorption, FVIII/FIX, desmopressin and antifibrinolytics. Haemophilia 2006; 12(Suppl. 6): 62-6.
41. Hayashi T, Tanaka I, Shima M et al. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor. Haemophilia 2004; 10: 397-400.
42. Schneiderman J, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia 2004; 10: 347-51.
43. Watts RG. Successful use of recombinant factor VIIa for emergency fasciotomy in a patient with hemophilia A and high-titer inhibitor unresponsive to factor VIII inhibitor bypassing activity. Am J Hematol 2005; 79: 58-60.
44. Mauser-Bunschoten EP, Koopman MM, Goede-Bolder AD et al. Efficacy of recombinant factor VIIa administered by continuous infusion to haemophilia patients with inhibitors. Haemophilia 2002; 8: 649-56.
45. Hoots WK. A "joint" statement on inhibitor-bypassing therapy. Blood 2007; 109: 395-6.
46. Donfield SM, Astermark J, Lail AE, Gilbert SA, Berntorp E for the FENOC Study Group. Value added: Increasing the power to assess treatment outcome in joint haemorrhages. Haemophilia 2008; 14: 276-80.
47. Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: A single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost 2003; 1: 450-5.
48. Dargaud Y, Bordet J, Baglin T, Négrier C. Monitoring the factor VIII/factor IX bypassing agents by calibrated automated thrombin generation test [abstract]. Haemophilia 2006; 12(Suppl. 2): 57.
49. Barrowcliffe TW, Cattaneo M, Podda GM et al. New approaches for measuring coagulation. Haemophilia 2006; 12(Suppl. 3): 76-81.
50. Váradi K, Turecek PL, Schwarz HP. Thrombin generation assay and other universal tests for monitoring haemophilia therapy. Haemophilia 2004; 10(Suppl. 2): 17-21.